Why A Structured System Matters 
How The System Helps You Succeed 
How Implementation Works 
What’s Included in the System 
Real Practice Outcomes 
Scaling a Profitable Practice 
Patient Demand 
Patient Education 
Staff Education 
Marketing 
Regenerative Medicine Platform
Franchise & PE Support 
Wharton’s Jelly
Exosomes
Anti-Aging
Aesthetic Treatments
Neurological
Autoimmune
Wound Care
Orthopedic Conditions
Clinical Trials
Articles
Research Institutes
GLP-3 (LY3437943) is a peptide most like the multi-agonist peptide developed by Eli Lilly known as “retta…”. It is a long-acting synthetic analog that activates three key metabolic pathways: GLP-3 (glucagon-like peptide-3), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. By targeting these receptors simultaneously, GLP-3 is being studied for its potential to deliver greater weight loss and metabolic improvements compared to single or dual agonists. It is not FDA-approved and remains in clinical research trials.
How The Peptide Is Used in Research Settings
- Studied for weight management and obesity through appetite suppression, enhanced satiety, and increased energy expenditure.
- Investigated in type 2 diabetes for improving glycemic control via insulin stimulation and glucagon modulation.
- Explored for cardiovascular risk reduction through effects on lipid metabolism and systemic inflammation.
- Examined in liver health research, including non-alcoholic fatty liver disease (NAFLD) and NASH models.
Proposed Uses (Research Areas)
- Obesity and advanced weight management research.
- Type 2 diabetes and metabolic syndrome studies.
- Cardiovascular and lipid health research.
- Liver disease research (NAFLD/NASH).
How It Is Dosed in Research Settings
- Injectable (Subcutaneous): Clinical studies have investigated doses ranging from 0.5 mg to 12 mg, administered once weekly.
- Titration: Doses are typically escalated gradually over weeks to reduce gastrointestinal side effects.
- Cycle length: Research trials extend 24–48 weeks or longer to measure sustained weight loss and metabolic effects.
- Handling: Provided as solution for injection in clinical research; stored refrigerated and protected from light.
Important Considerations
- Regulatory status: GLP-3 is not FDA-approved; it remains under clinical investigation.
- Evidence base: Early clinical data suggest superior weight loss compared to GLP-1 and GLP-2, though long-term safety and efficacy remain under study.
- Safety: Reported side effects in trials include nausea, vomiting, diarrhea, constipation, and GI discomfort. Long-term effects are not yet established.
Disclaimer
This material is provided for educational purposes only and summarizes published research on GLP-3.
It is not medical advice. GLP-3is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.
This peptide is for research use only.